Evidence
Gut Liver. 2023 Aug 10. doi: 10.5009/gnl220545. Online ahead of print.
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, and there has been a rapid increase in cases worldwide. NAFLD is rapidly becoming the leading cause of hepatocellular carcinoma and is also associated with an increased risk of cardiovascular disease or exacerbation of other organ diseases, thus posing a significant health problem from both a medical and a socioeconomic perspective. NAFLD is a systemic disease and requires the involvement of numerous medical professionals. Multidisciplinary collaboration, in which different professionals within different specialties come together and work together toward a common goal, supports better patient care by integrating perspectives of multiple experts and facilitating the exchange of opinions. Due to the large number of potential patients, gastroenterologists and hepatologists cannot manage the patients alone, and collaboration between specialists in various fields, including family doctors, dentists, nutritionists, and pharmacists is required for treatment of NAFLD. This review will discuss NAFLD from the perspective of various specialties and introduce multidisciplinary collaboration.
PMID:37560797 | DOI:10.5009/gnl220545
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
🌐 90 Days
VR Related Evidence Matrix
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- The gut-liver axis in fatty liver disease: role played by natural products
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- Association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a nationwide population‑based cohort study
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- The Association between Educational Attainment and the Risk of Nonalcoholic Fatty Liver Disease among Chinese Adults: Findings from the REACTION Study
- Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
- Muscle strength and non-alcoholic fatty liver disease/metabolic-associated fatty liver disease
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis
- Prevalences of Hypertension, Type 2 Diabetes Mellitus, and Cardiovascular Disease in a Cohort of Puerto Ricans with Non-alcoholic Fatty Liver Disease
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- The double roles of T cell-mediated immune response in the progression of MASLD
- Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus
- Serum Vitamin D Level in Overweight Individuals and Its Correlation With the Incidence of Non-alcoholic Fatty Liver Disease
- Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine
- Spleen volume is independently associated with non-alcoholic fatty liver disease, liver volume and liver fibrosis
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- EXPRESS: Association of Statins with Onset and Progression of Non-Alcoholic Fatty Liver Disease in Patients with Diabetes
- Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features
- Role of FXR in the development of NAFLD and intervention strategies of small molecules
- Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
- Plastic compounds and liver diseases: Whether bisphenol A is the only culprit
- Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
- Independent Associations of Aortic Calcification with Cirrhosis and Liver Related Mortality in Veterans with Chronic Liver Disease
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- Comparison of size of the liver between patients with non-alcoholic fatty liver disease and healthy controls
- COVID-19 in Individuals with Chronic Liver Diseases
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Bacteroides fragilis aggravates high-fat diet-induced non-alcoholic fatty liver disease by regulating lipid metabolism and remodeling gut microbiota
- Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease
- The Global Epidemic of Metabolic Fatty Liver Disease
- Investigating the Role of Non-Coding RNA in Non-Alcoholic Fatty Liver Disease
- The role of endoplasmic reticulum stress-related genes in the diagnosis and subtyping of non-alcoholic fatty liver disease
- Spatial genomics: mapping human steatotic liver disease
- Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease
- Mitochondrial ACSS1-K635 acetylation knock-in mice exhibit altered metabolism, cell senescence, and nonalcoholic fatty liver disease
- Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk
- Association between sleep duration and a new onset of nonalcoholic fatty liver disease
- 3D microscaffolds with triple-marker sensitive nanoprobes for studying fatty liver disease in vitro
- Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
- Erythropoietin hyporesponsiveness in non-alcoholic fatty liver disease
- Metabolic Derangement in Non-Alcoholic Fatty Liver Disease: Opportunities for Early Diagnostic and Prognostic Markers
- The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice
- Emerging roles of RNA-binding proteins in fatty liver disease
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
- Epidemiology, screening, and Co-management of type 2 diabetes mellitus and Metabolic-dysfunction associated steatotic liver disease
Evidence Blueprint
Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Nonalcoholic Fatty Liver Disease as a Systemic Disease and the Need for Multidisciplinary Care
🌐 365 Days
VR Related Evidence Matrix
- Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease
- MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
- Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases
- NASH drug treatment development: challenges and lessons
- Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver?
- MAFLD as part of systemic metabolic dysregulation
- MAFLD as part of systemic metabolic dysregulation
- Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
- Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets
- Occult liver disease: a multinational perspective
- Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
- Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies
- Hepatic, Extra-hepatic Outcomes and Causes of Mortality in NAFLD - An Umbrella Overview of Systematic Review of Meta-Analysis
- Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step?
- Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease
- Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota
- Corrected and republished from: Metabolic associated liver disease
- From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences
- Carbon Dots as Potential Therapeutic Agents for Treating Non-Alcoholic Fatty Liver Disease and Associated Inflammatory Bone Loss
- Akkermansia muciniphila - a Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease
- Hormone action and liver disease, a complex interplay
- Type 2 Diabetes Mellitus and Liver Disease: Across the Gut-Liver Axis from Fibrosis to Cancer
- Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort
- Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
- Impacts of gut microbiota alteration on age-related chronic liver diseases
- A survey on the awareness, current management, and barriers for non-alcoholic fatty liver disease among the general Korean population
- SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
- Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
- Non-alcoholic fatty liver disease in women - Current knowledge and emerging concepts
- Diabetes and fatty liver: Involvement of incretin and its benefit for fatty liver management
- The gut-liver axis in fatty liver disease: role played by natural products
- Research progress on the histological scoring system for nonalcoholic fatty liver disease
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
- Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth
- Gut microbiota metabolite TMAO promoted lipid deposition and fibrosis process via KRT17 in fatty liver cells in vitro
- Non-alcoholic fatty liver disease-related hepatocellular carcinoma
- The Role of Platelets in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics
- Enhanced non-alcoholic fatty liver detection: Computed tomography scan image analysis and noise reduction with morphological dilation
- Metabolic dysfunction: The silenced connection with fatty liver disease
- Impact of Porphyromonas gingivalis-odontogenic infection on the pathogenesis of non-alcoholic fatty liver disease
- New Insights into Nutrition and Gut-Liver Axis: A Focus on Non-Alcoholic Fatty Liver Disease
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- Association of thyroid disease and risk of fatty liver disease: an exposure-wide Mendelian randomization study
- Macrophage heterogeneity role in NAFLD and NASH disease progression
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Crohn´s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease
- Comprehensive analysis of epigenetic and epitranscriptomic genes' expression in human NAFLD
- Fatty liver disease's renaming impacts on drug clinical trials
- How non-alcoholic fatty liver disease and cirrhosis affect the heart
- The relationship between alcohol consumption and chronic kidney disease in patients with nonalcoholic fatty liver disease
- MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study
- Association between nonalcoholic fatty liver disease and incidence of inflammatory bowel disease: a nationwide population‑based cohort study
- Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
- Leukocyte cell-derived chemotaxin 2 correlates with pediatric non-alcoholic fatty liver disease
- Dysregulation of Lipid and Glucose Metabolism in Nonalcoholic Fatty Liver Disease
- Non-Alcoholic Fatty Liver Disease as an Emerging Risk Factor for Heart Failure
- Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies
- Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease
- Impact of Endoscopic Sleeve Gastroplasty in Non-alcoholic Fatty Liver Disease: a Systematic Review and Meta-analysis
- Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics